PDCD1 and melanoma: Knocking down FTO in melanoma enhances sensitivity to anti-PD-1 and IFN therapies by suppressing PD-1 (PDCD1), CXCR4, and SOX10 expression through YTHDF2-mediated mRNA decay, but it does not affect PD-L1 (CD274).112